Skip to content

Free UPS Ground on Orders $150+ 🇺🇸 Free UPS 2nd Day Air on Orders $250+ 🇺🇸 Free UPS Next Day Air on Orders $600+ 🇺🇸 Shipping Across the USA & Puerto Rico 🇺🇸 Third-Party Tested • Batch-Level COAs Available 🇺🇸 For Laboratory Research Only

Rewards available:View account

Explore Vertex

For laboratory research use only.

info@vertexpeptideslab.org

Peptide Impurities: Types, Origins and How Labs Detect Them

· Vertex Labs Editorial Team

Synthetic peptide impurities fall into two groups: peptide-related impurities, which share structural elements with the target sequence, and non-peptide impurities, such as residual solvents, counter ions and elemental contaminants. Each group has distinct origins in synthesis, purification, handling and storage, and each is detected with different analytical tools. This guide explains the common types, how they form, how liquid chromatography and mass spectrometry characterize them, and what a purity figure or Certificate of Analysis can and cannot tell a research team.

For Research Use Only. Not for human or veterinary use.

Vertex Labs
Review Research Materials With Batch Documentation
Vertex Labs supplies research-use-only peptides and laboratory compounds. Review the available third-party test reports and batch-specific documentation for the selected product and lot.

TL;DR

  • Peptide-related impurities include deletion and insertion sequences, truncated or incompletely deprotected species, isomers, oxidized or deamidated forms, disulfide variants and aggregates.
  • Non-peptide impurities include residual solvents, process reagents, elemental impurities and counter ions such as trifluoroacetate (TFA).
  • Impurities arise during chain assembly, cleavage, purification and storage, so lot-level analysis matters more than a single headline number.
  • LC-HRMS is a primary tool for identifying and quantifying impurities, including species that co-elute with the main peak.
  • Pharmaceutical impurity thresholds do not apply to research material, but they give laboratories a useful frame for documentation expectations.

Table of Contents

The two main categories of peptide impurities

The European Medicines Agency’s guideline on synthetic peptides defines peptide-related impurities as those that contain structural elements of the peptide sequence, and it separates them from non-peptide impurities such as residual solvents, elemental impurities and process reagents (European Medicines Agency, 2025). The distinction is practical. Peptide-related species often behave similarly to the target in chromatography and can be biologically or chemically active in an assay. Non-peptide species are usually removed by different means and can interfere with an experiment in different ways, for example by altering pH, ionic strength or cell viability in a culture.

A research team reading a COA or planning an assay should therefore ask two separate questions: what other peptide species are present, and what else is in the vial besides peptide.

Comparison of peptide-related impurities and non-peptide impurities

These species differ from the intended sequence by one or more residues or by a chemical modification. FDA-affiliated research describes them as amino acid sequences that differ from the active ingredient through insertion, deletion or other modifications such as oxidation or glycosylation (FDA/CDER presentation, 2017).

Impurity type What it is Typical origin
Deletion sequence Target missing one or more residues Incomplete coupling or inefficient deprotection during assembly
Insertion sequence Target with an extra residue Excess amino acid reagent carried into a later cycle
Truncated sequence Chain that stopped before completion Failed coupling steps, capping
Incompletely deprotected sequence Side-chain protecting groups still attached Incomplete cleavage
Oxidized species Typically methionine or tryptophan modifications Handling, storage, exposure to oxygen
Deamidated species Asparagine or glutamine converted to acidic residues Degradation in solution or on storage
Isomers and racemized species Altered stereochemistry at one or more residues Activation and coupling chemistry
Disulfide variants Reduced monomers, dimers, higher polymers Folding and oxidation steps
Aggregates Dimers and oligomers Covalent or noncovalent association during synthesis or storage

Deletion, insertion and truncation

Deletion and insertion products are the classic assembly impurities in solid-phase peptide synthesis (SPPS). A 2014 review of related impurities in peptide medicines links deletions to inefficient Fmoc deprotection and insertions to the excess use of amino acid reagents (PubMed, 2014). Because a deletion sequence differs from the target by a single residue, it can be very close in hydrophobicity and mass, which makes it difficult to resolve on a short gradient.

In-process controls such as the Kaiser test are used to monitor coupling and deprotection during assembly, although a 2019 technical report notes they may not prevent every deletion sequence (Polypeptide technical report, 2019). That is one reason final-product analysis, not process monitoring alone, is the basis for lot release.

Degradation products

Impurities do not only form during synthesis. The same 2014 review documents degradation routes including beta-elimination, diketopiperazine formation, pyroglutamate formation and succinimide formation (PubMed, 2014). Oxidation and deamidation are also commonly listed among degradation pathways for peptides. Because these reactions continue after the lot is released, the purity of a vial on the day of analysis is not necessarily the purity on the day of use. Storage conditions, container closure and handling history all matter, which is why we recommend recording receipt date, storage temperature and freeze-thaw history for every lot in a laboratory notebook.

For peptides containing cysteine pairs, disulfide bond modifications are a recognized impurity class. These include reduced monomers, parallel and anti-parallel dimers and higher polymers (Polypeptide technical report, 2019). Such species can share the same or nearly the same mass as the target, so mass alone may not distinguish them. Retention time, reduction and alkylation experiments and orthogonal methods become important.

Aggregates and high molecular weight species

High molecular weight impurities, including aggregates, dimers and oligomers, can form through covalent or noncovalent linkages during synthesis or storage (European Medicines Agency, 2025). Standard reversed-phase conditions can dissociate noncovalent aggregates, so a clean reversed-phase trace does not by itself rule them out. Size-exclusion chromatography is a common complementary approach when aggregation is a concern for an assay.

Non-peptide impurities

These species contain no peptide sequence but are present because of how the material was made and isolated.

  • Counter ions. Unintended counter ions such as trifluoroacetate (TFA) are common in final peptide products, arising from the SPPS process or later purification steps (PubMed, 2014). A lyophilized powder is therefore a salt, and its net peptide content is lower than its gross weight. Researchers who prepare solutions by mass should account for this when designing concentration-response experiments.
  • Residual solvents and reagents. Cleavage cocktails, scavengers, coupling reagents and purification solvents can persist in trace amounts.
  • Elemental impurities. Metals can enter from reagents, resins or equipment.
  • Water. Lyophilized peptides are often hygroscopic, so moisture content affects the true peptide mass per vial.

Amino acid raw materials themselves can be a source. The 2019 technical report lists impurities in amino acid raw materials alongside incomplete coupling and degradation as causes of peptide impurities (Polypeptide technical report, 2019). Cross-contamination from shared equipment is a related manufacturing concern, and a risk-based cleaning validation strategy is one way manufacturers structure the control of carryover between products. We cover entry points and detection in more detail in our guide to peptide contamination sources.

How impurities arise across the lifecycle

It helps to think in stages, because each stage has its own characteristic by-products.

  1. Raw materials. Protected amino acids and resins carry their own impurity profiles. The FDA refers sponsors to USP chapter 1504 for quality attributes of starting materials such as the resins used in chemical synthesis of therapeutic peptides (IPQ, 2024).
  2. Chain assembly. Incomplete coupling and deprotection produce deletions, truncations and insertions.
  3. Cleavage and deprotection. Residual protecting groups and side-chain modifications appear here.
  4. Purification and isolation. Preparative chromatography removes many related species and introduces counter ions and solvents. Lyophilization fixes the final salt form and water content.
  5. Storage and handling. Oxidation, deamidation, aggregation and other degradation reactions proceed over time.

A risk-based approach that links process parameters to critical quality attributes is described in the peptide characterization literature (Lian et al., 2021). The same logic applies at research scale: identify which stages are most likely to affect your assay, and request documentation that addresses them.

How laboratories detect and measure impurities

Reversed-phase HPLC with UV detection is the standard purity assay, and it reports the main peak as a percentage of total integrated peak area. It is valuable but limited to species that separate and absorb at the detection wavelength.

Liquid chromatography coupled to high-resolution mass spectrometry adds identity. A 2015 study in the AAPS Journal describes LC-HRMS as a highly effective approach that can quantify co-eluting species and confirm amino acid composition and sequence (AAPS Journal, 2015). Review literature also covers LC-MS characterization of synthetic peptide impurities, including structural isomers and stereoisomers (Lian et al., 2021).

A practical analytical panel for a research lot commonly combines:

  • HPLC or UPLC for chromatographic purity
  • Intact mass by MS for identity
  • MS/MS or other sequence confirmation where the sequence matters to the study
  • Water and counter ion determination when mass-based preparation is needed
  • Sterility or endotoxin testing for solutions intended for cell-based work

For sequence-level methods, see our overview of peptide sequence characterization methods.

What a purity value and a COA do and do not tell you

A purity percentage is a statement about one method under one set of conditions. Several points follow from that, and they are standard laboratory reasoning rather than claims about any single supplier.

Purity is method-specific. A value of 99% by one gradient and wavelength can look different on a different column or with mass-based detection. Ask which method, column, gradient and detection wavelength produced the number.

Area percent is not mass percent. Chromatographic purity reports peptide-related composition by peak area. It does not reflect water, counter ions or salts, so it is not the same as net peptide content.

Co-eluting species can hide. Isomers, racemized forms and some disulfide variants may sit under the main peak. This is why orthogonal confirmation, such as high-resolution MS, adds information.

A COA describes a lot at a point in time. It should carry a lot number that matches the vial, the test date and the methods used. Degradation after release is not captured, so storage records matter.

Identity and purity are separate questions. A clean chromatogram of the wrong molecule is still the wrong molecule. A complete COA includes a measured mass or equivalent identity evidence next to the purity result.

A useful checklist when reviewing a COA:

  1. Does the lot number match the product in hand?
  2. Is the test method named, with detection conditions?
  3. Is an observed mass reported against the theoretical mass?
  4. Is the testing laboratory identified, and is it independent of the manufacturer?
  5. Are water, counter ion or net peptide content values given when you will prepare solutions by weight?

Our Certificates of Analysis page shows how we present batch documentation, and our vendor evaluation criteria list further questions worth asking any supplier.

Why impurity profiles matter for assay design

Impurities are not only a manufacturing concern. The 2014 review notes that peptide-related impurities and degradants can lead to erroneous conclusions in early functionality studies (PubMed, 2014). A small, potent related species can shift an apparent concentration-response curve, and a counter ion or residual solvent can affect a cell-based readout independently of the peptide.

Several habits reduce that risk:

  • Use a single lot across a linked series of experiments, and record the lot number in every dataset.
  • Include appropriate vehicle and counter ion controls where the assay is sensitive.
  • Re-verify identity and purity on retained material if results drift between experiments.
  • Keep storage conditions consistent and documented.

Pharmaceutical thresholds as a reference point

Drug-product regulations set explicit limits, and they illustrate how seriously impurity control is treated in regulated settings. For generic peptide products covered by the FDA’s ANDA guidance, each peptide-related impurity should be identified at 0.10% or above, and applicants should show that no new peptide-related impurities exceed 0.5% (FDA, 2022). These figures apply to a defined regulatory pathway for drug products. They are not specifications for research-use material, and they should not be read as such. Industry practice also varies: a benchmark survey by the IQ Consortium found that impurity thresholds differed widely between organizations, and it proposed recommendations to harmonize control strategies (Organic Process Research & Development, 2025).

For regulatory questions about research-use-only products, consult current agency guidance and qualified counsel. Our summary of research peptide regulations for U.S. labs points to primary sources.

Our perspective

Impurity control is a documentation problem as much as a chemistry problem. A purity number without a lot, a method and an identity result leaves a laboratory unable to interpret its own data.

At Vertex Labs, we encourage researchers to review the product page and the available batch-specific Certificate of Analysis for the selected presentation. Documentation availability, test coverage and reported results vary by lot. Our published purity standard does not replace the findings of an individual laboratory report; assess the actual results and methods reported for the material selected.

We also encourage researchers to read COAs critically: check the method, the observed mass and the lot match, and ask for more where an assay depends on it. A supplier that welcomes those questions is easier to work with over the length of a project. Our manufacturing quality benchmarks guide sets out what we consider a reasonable baseline.

Vertex Labs Editorial Team

Sourcing documented research material

If your project needs lot-level documentation, we supply laboratory-grade research peptides, blends, sterile solutions and custom sequences. Check the product page and available batch-specific COA for the selected presentation; documentation and reported results vary by lot. Institutions can also ask about bulk procurement.

Vertex Labs research products website

Browse the research catalog or visit Vertex Labs to review product lines and request custom synthesis. For Research Use Only. Not for human or veterinary use.

FAQ

They are impurities that retain structural elements of the target peptide sequence, such as deletion, insertion, truncated, oxidized, deamidated or isomeric forms. The European Medicines Agency uses this definition and contrasts them with non-peptide impurities like solvents and reagents. They matter because they often behave much like the target in separations and assays.

Is a 99% purity result enough to trust a peptide lot?

It is a useful start, but it describes one method on one lot. Confirm the method, the observed mass against theoretical mass, the lot number and the testing laboratory. Water and counter ion content also affect how much peptide a vial actually contains.

Why is TFA found in synthetic peptides?

Trifluoroacetate is used in cleavage and reversed-phase purification, so it commonly remains as a counter ion in the final lyophilized product. Researchers who prepare solutions by weight, or who run sensitive cell-based assays, should account for it in their calculations and controls.

Can impurities form after a peptide is made?

Yes. Oxidation, deamidation, aggregation and other degradation reactions can continue during storage. Recording storage conditions and handling history for each lot helps explain changes in analytical or assay results over time.

Sources

Hey AI, learn about this page

Your Cart

Loading your cart…

Shipping and tax confirmed at checkout.

View full cart